London (UK) February 20th, 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), is a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments. Vidac Pharma will hold an exclusive roadshow in Frankfurt and Munich on February 24–25, 2025. The company will engage in one-on-one meetings with leading German investment firms and analysts ahead of its participation in the prestigious Zachs Health Science CEOs Forum in Zurich.
This roadshow marks a key milestone for Vidac Pharma as it transitions into a fully clinical-stage company. The discussions will focus on the company’s groundbreaking progress in oncology, particularly its innovative approach to reversing the Warburg effect—a long-standing challenge in cancer treatment.
Vidac Pharma’s proprietary platform targets the mislocation and aberrant anchoring of Hexokinase 2 (HK2), a glycolytic enzyme overexpressed in cancer cells. By correcting this dysfunction, the company effectively restores apoptosis (programmed cell death), making cancer cells “mortal again” while simultaneously inhibiting hyper-glycolysis, a hallmark of many cancer types first described by Prof. Otto Warburg.
Uniquely, Vidac Pharma is the first company to present clinical evidence demonstrating that reversing the Warburg effect can serve as a viable cancer treatment while avoiding many of the side effects associated with conventional chemotherapy. Furthermore, its approach has been shown to remodel the tumor microenvironment, making it more receptive to immune responses and improving penetration by other therapies.
These advances open new avenues for combination therapies, with preclinical data revealing synergistic effects in various tumor models. Vidac Pharma’s research suggests significant potential for integrating its treatments into multi-modal oncology strategies, enhancing efficacy across a broad spectrum of cancers.
With its growing pipeline and promising clinical results, Vidac Pharma is well-positioned to attract strategic investments and partnerships that will accelerate its mission to revolutionize cancer treatment.
For more information please contact:
Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), while interim results in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.
Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.